Skip to main content

Table 1 Characteristics of each study

From: Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis

First author Year Country Cancer types Sample size Cut off Median age Median follow-up (month) Research type Survival analysis HR type NOS
Mahmoud 2012 UK Primary invasive BC 1214 1 cell 55 250 Retrospective analysis BCSS Reported 6
Garaud 1 2019 Belgium HER2 + BC 136 0.055 NR 120 Retrospective analysis OS, DFS Reported 8
Garaud 2 2019 Belgium TNBC 113 0.0275 NR 120 Retrospective analysis OS, DFS Reported 8
Arias-Pulido 2018 Algeria IBC 221 0.01 NR 96 Retrospective analysis OS, DFS Estimated 5
Yeong 2018 Singapore TNBC 269 0.05 55 97 Retrospective analysis OS, DFS Reported 7
Xu 2018 China Invasive ductal BC 102 115 cells 48 60 Retrospective analysis OS, DFS Reported 6
Mohammed 2013 UK Primary operable ductal invasive BC 338 5 cells NR 164 Retrospective analysis BCSS Reported 8
Boissière-Michot 2020 France TNBC 105 NR NR 120 Retrospective analysis RFS Reported 7
Yu 2013 China BC 130 NR NR NR Retrospective analysis OS, DFS Estimated 6
  1. BC breast cancer; TNBC triple-negative breast cancer; IBC inflammatory breast cancer; HER2 human epidermal growth factor receptor-2; NR not reported; BCSS breast cancer-specific survival; OS overall survival; DFS disease-free survival; RFS relapse-free survival; HR hazard ratio; NOS Newcastle-Ottawa Quality Assessment Scale